Table 6. Medication use for upper and lower airway diseases of the study groups
Medications	Asthma	COPD		ACO	p
For Lower Airways
Inhaled corticosteroid (ICS)	39 (19.3%)	31 (26.3%)	23	(27.7%)	>0.05
Long-acting inhaled beta 2 agonists (LABA)	3 (1.5%)	29 (24.6%)	20	(23.8%)	<0.001
Short-acting inhaled beta 2 agonists	113 (55.4%)	66 (55.9%)	38	(45.2%)	>0.05
Combination of ICS-LABA	165 (80.9%)	78 (66.1%)	60	(70.6%)	0.009
Short-acting anticholinergics	6 (3%)	39 (33.1%)	13	(15.5%)	<0.001
Long-acting anticholinergics	4 (2%)	94 (79.7%)	53	(63.1%)	<0.001
Oral theophylline	6 (3%)	16 (13.6%)	18	(21.7%)	<0.001
Anti-Leukotrienes	101 (49.8%)	5 (4.2%)	17	(20.2%)	<0.001
For Upper Airways
Intranasal corticosteroids	52 (25.6%)	4 (3.4%)	9	(10.7%)	<0.001
Oral antihistamines	46 (22.7%)	0 (0%)	7	(8.3%)	<0.001